Pfizer blazes new research path

Taking a page from the biotech playbook, Pfizer has just inked a three-year, $9.5 million research collaboration pact with the University of California, San Francisco. The money will be used to fund early scientific work into new therapies and devices. Pfizer report

Suggested Articles

A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine.

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.